To analyze conformational changes associated with ligand binding, a difference distance matrix (DDM) was calculated by comparing the position of all C α atoms in the ligated Nrp2 b1 domain to the aligned C α atoms of the unligated structure (residues 277-427, RMSD = 0.2 Å). The two-dimensional DDM was reduced to one dimension by averaging the absolute change for each residue relative to all others. The DDM values were then used to generate a heat map with the regions of low to high conformational change represented across a yellow to red spectrum, respectively. (B) The one-dimensional DDM was mapped onto Nrp2-b1 to visualize the areas that undergo the largest conformational change upon ligand binding. Importantly, the major regions undergoing change are the coagulation factor loops that form the interloop cleft to which VEGF-C binds. 
SUPPLEMENTAL EXPERIMENTAL PROCEDURES
Protein expression and purification-Nrp2-b1b2 and variants were expressed as his-tagged proteins in E. coli from pET28b in E. coli strain Rosetta Gami-2(DE3) (Merck KGaA, Darmstadt, Germany) (Vander Kooi et al., 2007) . Nrp2-T319R was generated by megaprimer mutagenesis (Vander Kooi, 2013) . To generate the Nrp2/VEGF-C fusion, the five C-terminal residues of VEGF-C (219-SIIRR-223) were appended to the C-terminus of Nrp2-b1b2 (276-595) by incorporating the VEGF-C sequence into the reverse primer during cloning. Likewise, generation of s 9 Nrp2 involved primer incorporation of the sequence VGCSWRPL C-terminal to residues 275-547. All constructs and mutations were sequence verified. Proteins were purified via immobilized metal ion affinity chromatography (IMAC) (HIS-Select HF Nickel Affinity Gel, Sigma-Aldrich, St. Louis, MO) and eluted with 300 mM Imidazole, 200 mM NaCl, pH=8. Nrp2-b1b2, Nrp2-T319R, and the fusion protein were subsequently subjected to heparin affinity chromatography (HiTrap Heparin HP, GE Healthcare Life Sciences, Pittsburgh, PA).
Nrp2-b1 and s 9 Nrp2 B , which were incubated for 48 hours to facilitate production of the disulfide-linked dimer, were further purified by size exclusion chromatography (SEC) using a Superdex 75 HiLoad 16/60 column (GE Healthcare Life Sciences) equilibrated and run with 20 mM Tris pH 7.5, 100 mM NaCl.
Alkaline phosphatase (AP)-tagged mouse VEGF-C (residues 108-223) and the R223E mutant were produced from the pAP-tag5 vector and s 9 Nrp2 (residues 25-555; isoform O60462-6) and s 9 Nrp2 B were produced as a human growth hormone (Hgh)-fusion (Leahy et al., 2000) by transient transfection of Chinese Hamster ovary (CHO) cells (Aricescu et al., 2006; Longo et al., 2013) . AP-VEGF-C conditioned media was filtered, buffer exchanged into binding buffer (20 mM Tris pH 7.5, 50 mM NaCl), and concentrated. s 9 Nrp2 B was purified from conditioned media as above. Hgh-fusion proteins were detected by western blotting using an anti-Hgh antibody (1:10000 dilution, RDI-HGHabrX1, Fitzgerald
Industries, Acton, MA) (Parker et al., 2010) . Human VEGFR-3 extracellular domain (residues 21-776) was produced via baculovirus mediated expression in Spodoptera frugiperda 9 (Sf9) cells. Protein was purified from conditioned media using IMAC, the His-tag was removed using HRV-3C protease, and final purification was completed by SEC using a Superdex 200 HiLoad 16/60 column (GE Healthcare Life Sciences) equilibrated and run with 20 mM Tris pH 7.5, 100 mM NaCl.
Structure determination-For crystallization, the His-tag was removed from all proteins after IMAC purification by overnight incubation with thrombin and then further purified as indicated above.
The structure of the Nrp2-b1b2-VEGF-C fusion and Nrp2-T319R were solved by molecular replacement with wild-type Nrp2-b1b2 (PDB=2QQJ) used as a search model. The b1 domain alone (PDB=2QQJ residues 276-427) was used as a search model for the s 9 Nrp2 B molecular replacement solution.
Following molecular replacement, iterative modeling building and refinement was done using COOT (Emsley et al., 2010) and Refmac5 (Murshudov, 1997) to generate a final refined model (Table 1) . To characterize the interactions between VEGF-C and Nrp2 within the complex structure, the structure was analyzed using the PISA interaction server (http://www.ebi.ac.uk/ msd-srv/prot_int/pistart.html) and
Ligplot+ (Laskowski and Swindells, 2011) . Protein geometry was analyzed using MolProbity (Chen et al., 2010) . Superpose was used to calculate a difference density matrix (DDM) for the apo-Nrp2-b1b2
and complex structure (Maiti et al., 2004) . Graphics were prepared with Pymol molecular graphics software (www.pymol.org).
Plate-binding assay-For direct plate binding and soluble Nrp competition assays, Nrp2-b1b2
and Nrp2-T319R affinity plates were prepared by concentrating Nrp to 0.025 mg/mL and then diluting 1:10 with 50 mM Na 2 CO 3 pH 10.4. VEGFR3 affinity plates were prepared by diluting with Na 2 CO 3 to a final protein concentration of 0.010 mg/mL. The diluted protein stock and BSA (negative control) was then added to 96-well protein high-bind microplates (Corning 9018, Corning NY) for 1 hr at 37°C.
Following incubation, the plates were washed 5x 100 μL with PBS-T (PBS 0.1% Tween20) and stored at 4°C. AP-VEGF-C and AP-VEGF-C R223E was used at a final activity of 5 x 10 -1 u/mL. For direct binding assays, AP-VEGF-C or AP-VEGF-C R223E was directly added to Nrp2-affinity plates for 1 hr at RT. The plate was then washed 4x 100 μL with PBS-T, incubated for 5 min in the final wash, aspirated and then 100 μL of 1X AP substrate (Jardin et al., 2008) was added. The reaction was quenched with 100 μL of 0.5 M NaOH and the interaction was quantitated by reading absorbance at 405 nm on a microplate reader. For Nrp2 and VEGFR3 competition experiments, AP-VEGF-C was Q-purified prior to use. Nrp2 competition experiments were performed in binding buffer with 50 μg/mL heparin (Sigma Aldrich).
